Phenotyping Across Peripheral and Extra-musculoskeletal Domains
Build a reproducible domain record that distinguishes active inflammation, prior disease and functional impact before choosing treatment.
On this page
Describe what is active today
A disease label is a poor substitute for a phenotype. The same label may describe active oligoarthritis, enthesis-predominant symptoms, dactylitis, or controlled joint disease with persistent mechanical disability. Treatment decisions require a current domain record, while diagnostic reasoning also needs the cumulative history. Keep those two records connected but distinct.
Begin with an open account of what limits the patient, followed by a structured examination. Record the site, time course and objective support for each major symptom. “Peripheral disease active” is less useful than “two swollen ankles, plantar insertion pain with uncertain inflammatory contribution, no current dactylitis.” The second description makes both action and uncertainty visible.
Peripheral arthritis: count and characterize
Identify synovial swelling separately from tenderness, bony enlargement, edema and periarticular pathology. Record distribution, symmetry, joint size, range of motion and the functional consequences. A swollen knee that prevents walking can be more consequential than several minimally symptomatic small joints. Limited motion may reflect active synovitis, longstanding damage or another process.
Use a named joint-count system consistently. A 66-swollen/68-tender examination and a 44-joint examination cover different sets; they cannot be compared as if their raw numbers were interchangeable. A short 28-joint count is particularly liable to miss feet and other relevant peripheral sites. Clinical examination remains central; ultrasound can clarify uncertain synovitis when the result will change a decision. [1]
When findings are episodic, seek contemporaneous prior records and arrange reassessment during a meaningful flare where feasible. A patient’s photograph can help establish the chronology but does not reliably distinguish joint swelling from all surrounding causes. Avoid dismissing a credible history because the examination happens to be quiet, while also avoiding retrospective certainty that the available evidence cannot support.
Entheses: tenderness needs interpretation
Ask the patient to localize pain before palpation. Distinguish insertional pain from tendon-body pain, adjacent bursitis and referred pain. Examine both symptomatic sites and a consistent comparison set. Record recent loading, trauma, occupational demands, footwear, body habitus and widespread tenderness when relevant. These factors can coexist with inflammatory disease.
A clinical enthesitis index provides a reproducible count of tender sites, not histological proof of inflammation. The Leeds Enthesitis Index was developed in PsA and uses a small defined set of locations. [2] Its efficiency is useful, but a low score cannot describe every symptomatic enthesis. Add a site-specific note when the patient’s main problem falls outside the chosen index.
Ultrasound is most helpful when there is a genuine diagnostic or activity question. A DEUS analysis illustrates discordance between clinical tenderness and ultrasound-defined activity in axSpA/PsA. [3] That discordance should lead to interpretation of the particular tissue, technique and competing pain mechanisms, rather than assuming one measurement automatically invalidates the other.
Dactylitis: document the entire digit
Record the affected digit, current tenderness, duration, degree of diffuse swelling and functional effect. Distinguish current dactylitis from a credible past episode and from permanent enlargement. Assess adjacent skin, wounds, nail disease and focal tendon findings. A rapidly painful swollen digit after a puncture or with infection features requires a different urgency than a familiar inflammatory pattern.
For longitudinal comparison, count affected digits and retain a consistent approach to tenderness or circumference if used. Do not reduce a whole-digit lesion to the number of tender interphalangeal joints. Conversely, do not count every swollen finger as dactylitis when swelling is confined to one joint.
Skin, nails, bowel and eyes
Ask about current and previous psoriasis, then inspect accessible relevant sites with the patient’s consent. Scalp, retroauricular, umbilical and intergluteal disease may be missed by a routine exposed-skin examination. Nail pitting, onycholysis and dystrophy require clinical interpretation; uncertain lesions may warrant dermatology input. Record who established the diagnosis and whether current treatment may be suppressing visible lesions.
For bowel disease, distinguish established IBD from nonspecific symptoms. Persistent diarrhea, rectal bleeding, weight loss, nocturnal symptoms or iron deficiency may justify targeted gastrointestinal evaluation. Medication effects and other causes remain possible. The point is to identify a management-changing context, not to declare IBD from a symptom checklist.
For ocular history, distinguish documented anterior uveitis from an unspecified “red eye.” Recover ophthalmology records when feasible. A currently painful, photophobic red eye or reduced vision warrants urgent ophthalmic assessment. The phenotype should include recurrence and current activity because a remote resolved episode and frequently recurrent disease pose different treatment questions.
Axial disease is a separate assessment
Ask about onset, duration and character of back or buttock symptoms, stiffness, night pain and response to movement. These features influence suspicion but are not individually diagnostic. Evaluate mechanical and neurologic alternatives. Order axial imaging to answer a clinical question, with appropriate interpretation of inflammatory and structural lesions; do not order it merely to fill every possible classification box.
When axial disease is established, record whether it is currently driving treatment. “Peripheral SpA with back pain” and “active axSpA with peripheral arthritis” may require different evidence pathways even if both domains are present. Neither label erases the other domain.
A compact phenotype record
| Domain | Current activity | History and impact |
|---|---|---|
| Arthritis | Named swollen/tender count; sites and examination certainty | Prior documented episodes, damage, walking and hand function |
| Enthesis | Specified index plus symptomatic sites; inflammation confidence | Load, injury, prior imaging and occupational effect |
| Dactylitis | Digit count, tenderness and diffuse swelling | Prior episodes and residual enlargement |
| Axial | Current symptoms and objective assessment where indicated | Chronology, prior imaging and previous diagnosis |
| Extra-musculoskeletal | Skin/nail, bowel and eye activity | Confirmed diagnoses, recurrence and other specialists’ plans |
| Patient impact | Pain, fatigue, participation and a concrete priority | Change from baseline and noninflammatory contributors |
Translate phenotype into a decision
The domain-based approach in PsA guidance is a useful organizational comparison, while the treatment recommendations themselves remain PsA-specific. [4] For non-psoriatic pSpA, describe where treatment evidence is direct and where it is borrowed. First settle which inflammatory domain needs treatment; then consider associated organ disease, safety, previous exposure and patient priorities.
End the visit with a measurable target: less swelling, restored walking tolerance, recovery of hand function, or clarification of uncertain enthesis symptoms. At the next visit, compare the same domains. A changing global score should trigger inspection of its components rather than an assumption that all tissues improved or worsened together.
Evidence in context
Source status checked October 6, 2026. Population applicability and publication maturity are separate judgments.
Scrollable evidence table
| Source | Population and phenotype | Design and status | Applicability | Clinical implication | Important limitation | Last checked |
|---|---|---|---|---|---|---|
| EULAR early arthritis [1] | Early inflammatory arthritis | Guideline; peer-reviewed | General diagnostic approach | Clinical examination guides further testing | Not a pSpA-specific treatment guideline | 2026-10-06 |
| LEI development [2] | PsA | Instrument development; peer-reviewed | PsA-derived assessment | Standardize specified enthesis sites | Limited anatomical coverage; tenderness is nonspecific | 2026-10-06 |
| DEUS examination comparison [3] | AxSpA and PsA | Cross-sectional; peer-reviewed | Mixed SpA phenotypes | Clinical and ultrasound findings may disagree | No universal treatment threshold from discordance | 2026-10-06 |
| GRAPPA [4] | PsA domains and related conditions | Guideline; peer-reviewed | PsA-derived framework | Assess all active domains and impact | Do not relabel drug recommendations as direct non-psoriatic pSpA evidence | 2026-10-06 |